Mederi Therapeutics launched of RFT3, the third generation of Stretta technology.
Boston Scientific reported 2016 first quarter sales of $1.96 billion. Additionally, Michael Phalen, acting executive vice president and president-MedSurg of Boston Scientific, recently sold 35,000 shares of the firm.
Galmed Pharmaceuticals in New York signed an investigator-initiated clinical trial agreement with the Icahn School of Medicine at Mount Sinai in New York to evaluate the effect of aramchol in combination with vitamin D for treatment of nonalcoholic fatty liver disease.
Tobira Therapeutics announced results from a 12-week interim analysis of the Phase 2a ORION study, which showed treatment with its drug, cenicriviroc, was well tolerated and associated with improvements in insulin sensitivity.
EndoChoice appointed William Enquist as chairman of the board of directors.
More articles on GI/endoscopy:
Texas Medical Association names Dr. Carlos Cardenas president-elect: 3 points
Mederi Therapeutics launches 3rd generation of Stretta technology: 5 things to know
Boston Scientific’s net sales of $1.96B in Q1 2016: 7 key notes
